Table 1.
CSCs Contribute to Macrophage Recruitment | |||
Cancer Type | CSC-Derived Chemokines | Chemokine Receptors | References |
Glioma | OLFML3 | not shown | Chen et al., 2020b |
POSTN | αvβ3 integrin | Zhou et al., 2015 | |
CXCL12B | CXCR4 | Chia et al., 2018 | |
CCL5 and CX3CL1 | CCL5R and CX3CR1 | Guo et al., 2019b | |
Cholangiocarcinoma | POSTN | Αvβ3 integrin | Zeng et al., 2018 |
Lung cancer | TNF-α, IL-1β, and IL-6 | IL-6R | Lu et al., 2018 |
Bladder cancer | IL-6 and CCL2 | IL-6R and CCR2 | Kobatake et al., 2020 |
CRC | IL-33 | ST2 | Fang et al., 2017 |
Liver cancer | CCL2 and M-CSF | CCR2 and CSF1R | Guo et al., 2017 |
Breast cancer | M-CSF, CCL2, CCL5, and vascular endothelial growth factor A | not shown | Valeta-Magara et al., 2019 |
CSCs Contribute to Macrophage Polarization | |||
Cancer Type | CSC-Derived Chemokines | Mechanisms | References |
Glioma | IL-6, IL-10, M-CSF, TGF-b1, and MIC-1 | STAT3 pathway | Wu et al., 2010; Yao et al., 2016 |
WISP1 | α6β1 integrin/AKT pathway | Tao et al., 2020 | |
exosomes | STAT3 pathway | Gabrusiewicz et al., 2018 | |
Ovarian cancer | IL-10 and WNT | NF-κB pathway | Raghavan et al., 2019 |
Cholangiocarcinoma | IL-13, IL-34, and osteoactivin | not shown | Raggi et al., 2017 |
Bladder cancer | IL-6 and CCL2 | STAT3 pathway | Kobatake et al., 2020 |
Breast cancer | IL-6 | STAT3 pathway | Weng et al., 2019 |